Canine Traumatic Injury Stabilization (BodeVet/LoVLETR)

Background and Purpose of the Trial

Our pets can experience an unexpected traumatic event at any time causing serious physical injury. When that injury is severe, they may require blood products to help stabilize them. Blood products are traditionally stored in a liquid form requiring refrigeration or the ability to freeze. We are interested in finding platelet and plasma products that can be stored for extended periods of time at room temperature and will quickly and efficiently stabilize dogs suffering from traumatic injury to improve the care offered in veterinary hospitals.

Study Design

This clinical trial will evaluate the early application of a novel commercial freeze-dried platelet product (StablePlate RX®) and freeze-dried plasma product (StablePlas®) against the current standard of care for trauma management and stabilization. These new products are derived from dog platelets or plasma donated by healthy canine donors. The products have undergone preclinical testing on healthy dogs. These are the SAME blood products that your dog would likely receive for severe bleeding in trauma, only in a freeze-dried, readily available form. We are testing the use of these products to determine if they are superior to the current standard of care in canine trauma in an effort to improve survival outcomes and decrease the time and cost to stabilize canine patients following significant trauma.


There is a 30-day follow-up phone appointment.


Blood products received in the patient’s research arm are covered by the study. Specific serial bloodwork, evaluating metabolic function and coagulation, will be performed during the first four hours and up to 24 hours of resuscitation at no cost to the client. The estimated value of the blood products and bloodwork is up to $2000. In addition, the client will receive a $1700 credit to be used at their discretion.

Eligibility Information

Inclusion Criteria

  • Weigh between 5-60 kg
  • Patients must have experienced known blunt or penetrating trauma which has resulted in hemorrhage, OR have hemorrhagic shock from internal bleeding not related to a coagulopathy (e.g., rodenticide toxicity) or anaphylaxis.
  • The patient must be in cardiovascular shock from the hemorrhage
  • Shock index ≥1.1
  • ATT score ≥3
  • Client consent

Exclusion Criteria

  • Received blood products within 72 hours
  • Received greater than 10ml/kg of crystalloids after the trauma
  • Known heart congestive heart failure or hypertension
  • Surgery within 48 hours of enrollment

Contact Information

Auburn University Small Animal Teaching Hospital Emergency and Critical Care Services 334-844-4690